Barclays
NBP

Barclays’s NovaBridge Biosciences American Depositary Shares NBP Stock Holding History

Barclays’s Portfolio NBP Stock Details NBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$736K Sell
299,299
-329,624
-52% -$1.1M ﹤0.01% 2945
2025
Q4 		$2.5M Buy
628,923
+233,492
+59% +$1.03M ﹤0.01% 2775
2025
Q3 		$1.49M Buy
395,431
+365,061
+1,202% +$1.24M ﹤0.01% 3104
2025
Q2 		$73.5K Hold
30,370
– – ﹤0.01% 4644
2025
Q1 		$25K Hold
30,370
– – ﹤0.01% 4754
2024
Q4 		$25.8K Hold
30,370
– – ﹤0.01% 4883
2024
Q3 		$37.7K Hold
30,370
– – ﹤0.01% 4804
2024
Q2 		$50.7K Sell
30,370
-8,182
-21% -$14.6K ﹤0.01% 4209
2024
Q1 		$71.7K Sell
38,552
-134,512
-78% -$248K ﹤0.01% 4538
2023
Q4 		$329K Buy
173,064
+60,597
+54% +$90.5K ﹤0.01% 4150
2023
Q3 		$148K Hold
112,467
– – ﹤0.01% 3426
2023
Q2 		$336K Sell
112,467
-317,939
-74% -$1.02M ﹤0.01% 2988
2023
Q1 		$1.49M Buy
430,406
+101,106
+31% +$490K ﹤0.01% 2427
2022
Q4 		$1.38M Buy
+329,300
New +$1.25M ﹤0.01% 2546
2022
Q2 		– Sell
-240,881
Closed -$3.91M – 5139
2022
Q1 		$3.91M Buy
+240,881
New +$6.17M ﹤0.01% 1379

Other funds holding NBP

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
AIHC Capital Management Central $120M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Barclays's NBP Position: Q1 2026 in Review

Barclays reduced its NovaBridge Biosciences American Depositary Shares (NBP) stake by 52% in Q1 2026, selling an estimated $1.1M and leaving 299,299 shares worth $736K. The position accounts for ﹤0.01% of the portfolio, ranked #2945.

Barclays first reported a position in NBP in Q1 2022 and has held it in 15 quarters since. The position peaked at $3.91M in Q1 2022. 48 funds tracked by Wall St. Rank hold NBP as of Q1 2026.

  • Barclays held 299,299 shares of NovaBridge Biosciences American Depositary Shares worth $736K as of Q1 2026.
  • Barclays sold 329,624 NovaBridge Biosciences American Depositary Shares shares in Q1 2026, an estimated $1.1M.
  • NovaBridge Biosciences American Depositary Shares made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2945 holding.
  • Barclays first reported a position in NovaBridge Biosciences American Depositary Shares in Q1 2022 and has held it in 15 quarters since.
  • Barclays's NovaBridge Biosciences American Depositary Shares position peaked at $3.91M in Q1 2022.
  • 48 funds tracked by Wall St. Rank held NovaBridge Biosciences American Depositary Shares as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.